Global Drug Delivery Devices Market
The global drug delivery devices market is expected to reach USD 3,164.51 billion by 2031 from USD 1,748.63 billion in 2023, growing at a CAGR of 8.0% in the forecast period of 2024 to 2031.
Global Drug Delivery Devices Market, By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare, and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Drug Delivery Devices Market Dynamics:Driver
• Rising prevalence of chronic disease and non-chronic disease
Restraint
• High costs of injectable drugs
Opportunity
• Rising acceptance of self-administering drug devices
Market Players:
The key market players operating in the global drug delivery devices market are listed below:
• Johnson & Johnson Services, Inc.
• Novartis AG
• F.Hoffmann-La Roche Ltd
• Bayer AG
• Pfizer Inc.
• 3M
• AbbVie Inc.
• Amgen Inc.
• BD
• Elcam Medical
• Enable Injections
• Gerresheimer AG
• GSK plc.
• Insulet Corporation
• Medmix
• Merck & Co., Inc.
• OraSure Technologies Inc.
• Sanofi
• SMC Ltd.
• ViVO Smart Medical Devices Ltd.
• West Pharmaceutical Services Inc.